This is an old revision of this page, as edited by Citation bot 1 (talk | contribs) at 22:09, 2 May 2010 (Citation maintenance. Formatted: doi. You can use this bot yourself! Report bugs here.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:09, 2 May 2010 by Citation bot 1 (talk | contribs) (Citation maintenance. Formatted: doi. You can use this bot yourself! Report bugs here.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
Other names | (1R,3S,5Z)-5--7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
Routes of administration | Topical |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.220.855 |
Chemical and physical data | |
Formula | C27H44O3 |
Molar mass | 416.64 g·mol |
Tacalcitol is a synthetic vitamin D3 analogue.
Tacalcitol is marketed under several names, including Curatoderm and Bonalfa.
Mechanism
Tacalcitol exerts its biological activity by preventing the proliferation of keratinocytes.
Uses
It is used to treat psoriasis.
It has been used for vitiligo and Hailey-Hailey disease.
References
- Fukuoka M, Sakurai K, Ohta T, Kiyoki M, Katayama I (2001). "Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes". Skin Pharmacol. Appl. Skin Physiol. 14 (4): 226–33. PMID 11464105.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Leone G, Pacifico A, Iacovelli P, Paro Vidolin A, Picardo M (2006). "Tacalcitol and narrow-band phototherapy in patients with vitiligo". Clin. Exp. Dermatol. 31 (2): 200–5. doi:10.1111/j.1365-2230.2005.02037.x. PMID 16487090.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - Aoki T, Hashimoto H, Koseki S, Hozumi Y, Kondo S (1998). "1alpha,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro". Br. J. Dermatol. 139 (5): 897–901. doi:10.1046/j.1365-2133.1998.02522.x. PMID 9892963.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link)
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |
Drugs used for psoriasis (D05) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Topical |
| ||||||||
Systemic |
| ||||||||
|